Regencell Bioscience Holdings Limited (RGC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Regencell Bioscience Holdings Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Regencell Bioscience Holdings Limited (RGC) has returned 21.10% so far this year and 2,931.18% over the past 12 months.

Based on dividend-adjusted daily data since Jul 16, 2021, RGC's average daily return is +1.39%, while the average monthly return is +41.23%. At this rate, your investment would double in approximately 0.2 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2025 with a return of +1,361.7%, while the worst month was Mar 2022 at -40.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RGC closed higher 38% of trading days. The best single day was Jul 23, 2024 with a return of +343.9%, while the worst single day was Jun 20, 2025 at -40.0%.

Regencell Bioscience Holdings Limited has an annualized alpha of 3026.01%, beta of 0.41, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 19, 2021.

• This stock captured 61.12% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1718.17%) — a profile typical of hedging or uncorrelated assets.
• Beta of 0.41 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RGC ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Regencell Bioscience Holdings Limited (RGC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Regencell Bioscience Holdings Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Regencell Bioscience Holdings Limited was 93.09%, occurring on Jul 16, 2024. Recovery took 171 trading sessions.

The current Regencell Bioscience Holdings Limited drawdown is 67.40%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Regencell Bioscience Holdings Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Regencell Bioscience Holdings Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.